current
regist
treatment
infect
emerg
zoonot
coronavirus
like
sarsand
merscoronaviru
report
cultur
cell
lowmicromolar
concentr
alisporivir
nonimmunosuppress
cyclosporin
aanalog
inhibit
replic
four
differ
coronavirus
includ
mersand
sarscoronaviru
ribavirin
found
potenti
antivir
effect
alisporivir
cell
culturebas
infect
model
combin
treatment
unabl
improv
outcom
sarscov
infect
mous
model
nevertheless
data
provid
basi
explor
potenti
cyp
inhibitor
hostdirect
broadspectrum
inhibitor
coronaviru
replic
outbreak
sever
acut
respiratori
syndromecoronaviru
sarscov
continu
circul
middl
east
respiratori
syndromecoronaviru
merscov
sinc
highlight
potenti
lethal
consequ
zoonot
coronaviru
infect
human
approxim
peopl
infect
sarscov
epidem
mortal
http
wwwwhointcsrsarsen
global
mer
talli
laboratoryconfirm
case
mortal
http
wwwwhointcsrdiseasecoronaviru
infectionsen
air
travelrel
outbreak
south
korea
confirm
case
death
potenti
expos
individu
quarantin
illustr
socioeconom
impact
kind
emerg
pathogen
also
outsid
region
viru
endem
http
wwwwhoint
lack
effect
method
prevent
treat
coronaviru
infect
human
remain
seriou
public
health
concern
especi
given
increas
evid
sarslik
coronavirus
continu
circul
bat
may
potenti
readili
cross
speci
barrier
emerg
human
pathogen
ge
et
al
menacheri
et
al
data
cell
cultur
infect
model
chan
et
al
chan
et
al
de
wild
et
al
falzarano
et
al
kindler
et
al
zielecki
et
al
experi
rhesu
macaqu
falzarano
et
al
marmoset
chan
et
al
suggest
interferon
ifn
potent
inhibitor
merscov
replic
outcom
clinic
use
interferon
variabl
report
question
longterm
surviv
benefit
altawfiq
et
al
omrani
et
al
shalhoub
et
al
wherea
other
suggest
investig
warrant
khalid
et
al
possibl
combin
use
lopinavirritonavir
kim
et
al
unfortun
neg
outcom
confound
latestag
treatment
criticallyil
patient
sinc
develop
registr
novel
therapeut
compound
gener
time
consum
repurpos
approv
drug
offer
one
shortcut
establish
anticoronaviru
therapi
sever
fdaapprov
compound
report
inhibit
merscov
sarscov
replic
cell
cultur
de
wild
et
al
dyall
et
al
hart
et
al
efficaci
anim
model
remain
determin
previous
fdaapprov
drug
cyclosporin
csa
shown
inhibit
replic
varieti
virus
review
nagi
et
al
includ
coronavirus
carbajolozoya
et
al
de
wild
et
al
de
wild
et
al
kim
lee
pfefferl
et
al
http
tanaka
et
al
csa
target
member
cyclophilin
cyp
famili
peptidylprolin
isomeras
ppias
act
chaperon
protein
fold
function
davi
et
al
sinc
immuno
suppress
properti
csa
schreiber
crabtre
undesir
sideeffect
context
antivir
therapi
numer
nonimmunosuppress
cyp
inhibitor
develop
among
alisporivir
alv
show
increas
sustain
viral
respons
treatment
chronic
hepat
c
viru
hcv
infect
phase
iii
clinic
trial
treatment
ribavirin
pegyl
interferon
combin
alv
buti
et
al
flisiak
et
al
pawlotski
et
al
zeuzem
et
al
studi
first
investig
whether
alv
inhibit
mersand
sarscov
replic
cell
cultur
employ
previous
describ
cellcultur
base
screen
assay
reli
rapid
cytopath
effect
cpe
observ
coronavirusinfect
cell
de
wild
et
al
de
wild
et
al
first
viabil
merscovinfect
vero
cell
moi
treat
increas
alv
concentr
assess
day
post
infect
pi
found
virusinduc
cpe
prevent
alv
dosedepend
manner
ec
tabl
next
establish
alv
treatment
also
reduc
yield
infecti
merscov
progeni
vero
cell
infect
merscov
moi
treat
increas
noncytotox
alv
concentr
cell
viabil
data
see
fig
grey
line
h
post
infect
pi
onward
progeni
viru
merscovinfect
vero
cell
harvest
h
pi
titrat
plaqu
assay
reveal
log
reduct
use
alv
fig
effect
pronounc
cell
compar
decreas
progeni
titer
alreadi
observ
use
alv
fig
similar
result
obtain
use
fulli
differenti
primari
human
airway
epitheli
hae
cell
noncili
cell
shown
primari
target
merscov
infect
raj
et
al
first
airliquid
interfac
cultur
deriv
two
donor
cultur
day
semiperm
transwel
membran
van
weter
et
al
next
hae
cell
cultur
pretreat
h
alv
etoh
vehicl
control
infect
merscov
isol
moi
titer
determin
vero
cell
alv
treatment
merscov
progeni
titer
reduc
log
depend
donor
fig
second
laboratori
abil
alv
inhibit
merscov
replic
assess
independ
vero
cell
cell
inocul
merscov
moi
medium
contain
alv
ad
h
pi
supernat
collect
day
level
infecti
viru
progeni
assess
tcid
assay
parallel
toxic
assess
use
cell
viabil
assay
day
decreas
infecti
progeni
observ
dose
alv
ec
valu
calcul
vero
cell
respect
fig
tabl
sarscov
infect
moi
vero
cell
sensit
alv
fig
result
nearcomplet
block
use
alv
log
reduct
viru
progeni
could
achiev
cell
use
dose
fig
suggest
alv
treatment
cell
twice
less
effect
compar
vero
cell
sarscov
merscov
differ
alv
sensit
variou
cell
line
observ
one
explan
differ
would
alv
uptak
differ
per
cell
line
interestingli
also
observ
remark
differ
eg
sarscovinduc
cell
death
vero
cell
rang
sever
cpe
former
minim
cpe
latter
incub
period
unpublish
observ
suggest
relat
cell
line
respond
quit
differ
viru
infect
investig
potenti
alv
broadspectrum
coronaviru
inhibitor
assess
effect
alv
treatment
replic
two
addit
coronavirus
murin
hepat
viru
mhv
strain
human
coronaviru
follow
infect
moi
media
harvest
h
pi
mhv
cell
h
pi
cell
fig
h
use
alv
dose
mhv
progeni
titer
decreas
log
dose
result
reduct
without
show
sign
toxic
uninfect
cell
cell
viabil
valu
untreat
control
cell
observ
alv
concentr
test
data
shown
product
reduc
similar
extent
reduct
alv
respect
ribavirin
previous
report
inhibit
merscov
replic
falzarano
et
al
alv
ribavirin
use
togeth
clinic
trial
hepat
c
treatment
pawlotski
et
al
combin
test
cell
combin
ribavirin
alv
treatment
primarili
addit
effect
antivir
activ
except
combin
gml
ribavirin
alv
synergi
valu
fig
calcul
use
macsynergi
ii
prichard
shipman
increas
concentr
ribavirin
gradual
lower
cell
viabil
measur
without
affect
cellular
morpholog
assess
microscop
fig
find
suggest
combin
approach
might
chanc
success
anim
model
therefor
assess
whether
similar
inhibitori
effect
could
observ
mous
model
employ
mouseadapt
strain
sarscov
robert
et
al
anim
treat
daili
alv
mgkg
andor
ribavirin
mgkg
unfortun
treatment
alv
alon
enhanc
surviv
data
shown
combin
therapi
alv
ribavirin
prevent
weight
loss
fig
enhanc
surviv
fig
sinc
alv
concentr
requir
sarscov
inhibit
cell
cultur
higher
requir
inhibit
hcv
replic
coelmont
et
al
paeshuys
et
al
puyang
et
al
neg
outcom
anim
experi
may
surpris
nevertheless
use
cyp
inhibitor
remain
promis
innov
antivir
strategi
class
drug
potenti
inhibit
broad
rang
pathogen
virus
includ
hepat
b
viru
phillip
et
al
ec
hcv
coelmont
et
al
paeshuys
et
al
puyang
et
al
ec
valu
human
immunodefici
viru
ptak
et
al
ec
valu
lownanomolar
rang
previous
report
also
replic
two
arterivirus
distantli
relat
coronavirus
block
alvrel
nonimmunosuppress
csa
analog
de
wild
et
al
mockinfect
cell
receiv
alv
solvent
use
refer
cell
viabil
rel
viabil
set
cell
incub
day
except
merscov
cell
day
cell
viabil
monitor
use
celltit
aqueou
nonradioact
cell
prolifer
assay
promega
addit
potenti
toxic
alv
treatment
monitor
parallel
mockinfect
cell
cultur
graph
show
result
averag
sd
repres
experi
perform
quadrupl
viruscel
combin
test
least
twice
line
repres
rel
cell
viabil
absenc
infect
alv
toxic
control
bar
repres
rel
cell
viabil
infect
alv
treatment
viru
titer
cultur
medium
determin
plaqu
assay
describ
van
den
worm
et
al
c
hae
cell
two
differ
donor
cultur
semiperm
transwel
membran
week
h
prior
infect
alv
etoh
medium
ad
basal
side
cell
layer
subsequ
cell
apic
infect
merscov
moi
titer
determin
vero
cell
h
viru
releas
apic
side
cell
layer
determin
harvest
mucou
fluid
subsequ
plaqu
assay
e
f
sarscovinfect
e
vero
f
cell
moi
treat
variou
concentr
alv
h
pi
onward
viru
titer
cultur
medium
h
pi
determin
plaqu
assay
g
cell
infect
moi
h
cell
infect
moi
treat
alv
h
pi
onward
infecti
progeni
titer
determin
h
pi
h
pi
respect
graph
show
result
one
repres
experi
mean
sd
n
experi
control
infect
includ
cell
remain
untreat
treat
amount
etoh
equal
present
highest
alv
concentr
use
twosid
student
test
graphpad
prism
softwar
use
determin
signific
inhibit
viru
replic
etohtr
alvtreat
sampl
p
p
p
ns
signific
studi
reveal
alv
broadspectrum
coronaviru
inhibitor
cell
cultur
inhibit
replic
alphaand
betacoronavirus
fig
carbajolozoya
et
al
research
need
elucid
exact
mechan
action
underli
alv
interfer
coronaviru
replic
well
involv
cyp
coronaviru
replic
cycl
hcv
alv
shown
disrupt
function
interact
cyclophilin
cypa
viral
protein
andor
rna
coelmont
et
al
garciarivera
et
al
nag
et
al
interestingli
although
alv
time
higher
affin
cypa
compar
csa
unpublish
data
ec
valu
inhibitor
similar
leav
possibl
alv
cyp
inhibitor
target
cov
replic
independ
cypa
previou
studi
reduct
viru
progeni
report
upon
treatment
infect
cell
alv
ec
carbajolozoya
et
al
observ
variat
ec
valu
suggest
differ
coronavirus
may
equal
sensit
drug
although
may
also
reflect
differ
eg
experiment
design
cyp
express
level
andor
alv
uptak
turnov
differ
cell
line
lack
alv
activ
sarscov
anim
model
suggest
drug
may
suit
treatment
coronaviru
infect
nevertheless
cyp
inhibitor
remain
interest
lead
develop
hostdirect
anticoronaviru
therapi
well
interest
tool
studi
role
cyp
coronaviru
replic
detail
data
two
independ
laboratori
valu
calcul
describ
previous
de
wild
et
al
falzarano
et
al
select
index
si
rel
efficaci
compound
specif
inhibit
viru
replic
calcul
statist
analys
perform
use
result
least
two
independ
experi
valu
mean
se
repres
experi
n
repeat
least
twice
b
si
select
index
calcul
c
data
present
fig
viru
yield
determin
assay
data
present
fig
falzarano
et
al
e
experi
perform
independ
confirm
antivir
effect
alv
second
laboratori
gml
ribavirin
h
pi
onward
viru
titer
cultur
medium
day
pi
determin
previous
describ
falzarano
et
al
b
parallel
control
cell
treat
compound
concentr
determin
cytotox
celltit
aqueou
one
solut
cell
prolifer
assay
